Verastem Oncology (Nasdaq: VSTM) announced that the first patient has been dosed in the TARGET-D 202 Phase 2 registration-directed trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE